n.a. (OPTR)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Optimer Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Optimer Pharmaceuticals, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Optimer Pharmaceuticals, Inc.

Investigations Into Proposed Buyouts Of Optimer Pharmaceuticals, Inc., Trius Therapeutics, Inc. And Maidenform Brands, Inc. Announced By Holzer Holzer & Fistel, LLC

Investigations Into Proposed Buyouts Of Optimer Pharmaceuticals, Inc., Trius Therapeutics, Inc. And Maidenform Brands, Inc. Announced By Holzer Holzer & Fistel, LLC

Holzer Holzer & Fistel, LLC is investigating potential shareholder claims on behalf of investors who currently own Optimer Pharmaceuticals, Inc.

Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches An Investigation Of Optimer Pharmaceuticals, Inc. Over The Proposed Sale Of The Company To Cubist Pharmaceuticals, Inc.

Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches An Investigation Of Optimer Pharmaceuticals, Inc. Over The Proposed Sale Of The Company To Cubist Pharmaceuticals, Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Optimer Pharmaceuticals...

Milberg Announces Investigation Of Unfair Low Price In Cubist’s Acquisition Of Optimer

Milberg Announces Investigation Of Unfair Low Price In Cubist’s Acquisition Of Optimer

Milberg LLP is currently investigating the proposed acquisition of Optimer Pharmaceuticals, Inc.

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

The Deal: Cubist Commits $1.6B to Bolster Antibiotics Portfolio

Cubist Pharmaceuticals on Tuesday committed up to $1.6 billion to acquire two makers of next-generation antibiotics in a bid to expand aggressively its acute care product portfolio.

Finkelstein Thompson LLP Announces Investigation Of Optimer Pharmaceuticals, Inc. Buyout

Finkelstein Thompson LLP Announces Investigation Of Optimer Pharmaceuticals, Inc. Buyout

The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Optimer Pharmaceuticals, Inc.

Optimer Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Sale Of Optimer To Cubist

Optimer Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Sale Of Optimer To Cubist

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of Optimer Pharmaceuticals, Inc.

Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of Optimer Pharmaceuticals Proposed Acquisition By Cubist Pharmaceuticals, Inc.

Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of Optimer Pharmaceuticals Proposed Acquisition By Cubist Pharmaceuticals, Inc.

Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether members of the board of directors of Optimer Pharmaceuticals, Inc.

Comcast, Cubist Jump Pre-market Amid Cautious Trading

Comcast, Cubist Jump Pre-market Amid Cautious Trading

Stock futures are little changed Wednesday despite upbeat reports on GDP and jobs ahead of the Fed announcement.

Morning Briefing: 10 Things You Should Know

Morning Briefing: 10 Things You Should Know

U.S. stock futures suggest a flat to slightly higher start for Wall Street; Cubist Pharmaceuticals makes two acquisitions; MasterCard and Comcast highlight the earnings calendar.

SHAREHOLDER ALERT: Wohl & Fruchter Investigating The Acquisition Of Optimer Pharmaceuticals, Inc. By Cubist Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Wohl & Fruchter Investigating The Acquisition Of Optimer Pharmaceuticals, Inc. By Cubist Pharmaceuticals, Inc.

The law firm of Wohl & Fruchter LLP is investigating the proposed acquisition of Optimer Pharmaceuticals, Inc.

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys

Cubist Becomes Dominant Antibiotic Seller With Optimer, Trius Buys

Cubist announces two acquisitions in one day.

Cubist Pharmaceuticals To Acquire Optimer Pharmaceuticals

Cubist Pharmaceuticals To Acquire Optimer Pharmaceuticals

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Optimer Pharmaceuticals, Inc.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Commit To Purchase Optimer Pharmaceuticals At $10, Earn 36.5% Annualized

Commit To Purchase Optimer Pharmaceuticals At $10, Earn 36.5% Annualized

Investors eyeing a purchase of Optimer Pharmaceuticals Inc shares, but tentative about paying the going market price of $14.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $10 strike, which has a bid at the time of this writing of 30 cents.

Cubist, Optimer, Trius: Antibiotic Deal Making On Tap

Cubist, Optimer, Trius: Antibiotic Deal Making On Tap

The pace of deals among developers of antibiotics is about to ramp higher.

3 Biotech Stocks Spiking With Big Volume

3 Biotech Stocks Spiking With Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.